ArticleTranslational oncology2026
Cancer-associated fibroblasts-derived CAV1 promotes epithelial-mesenchymal transition and stemness in bladder cancer through activation of the LIF/STAT3 signaling pathway.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer-associated fibroblasts (CAFs) are key components of the bladder cancer microenvironment, but how specific CAF subpopulations drive malignant progression remains unclear. This study aimed to identify CAF driver genes and elucidate the role of caveolin-1 (CAV1) in CAF-mediated bladder cancer progression.
methodsSingle-cell RNA sequencing and public bladder cancer datasets were integrated to identify fibroblast-associated candidate genes and evaluate the clinical significance of CAV1. Clinical samples were analyzed by immunofluorescence. The biological functions of CAV1 were further evaluated through CAF-bladder cancer cell co-culture systems, gain- and loss-of-function experiments, and comprehensive molecular analyses. The downstream mechanism was explored through LIF stimulation, STAT3 silencing, and validated in a subcutaneous xenograft model.
resultsSingle-cell analysis identified CAV1 as a fibroblast-associated gene linked to stemness- and ferroptosis-related signatures. High CAV1 expression predicted poor prognosis and was independently associated with unfavorable survival. CAV1 expression positively correlated with fibroblast infiltration and was enriched in a subset of ACTA2-positive CAFs. CAFs markedly promoted multiple malignant behaviors of bladder cancer cells, whereas silencing CAV1 effectively counteracted these pro-tumorigenic effects. Mechanistically, CAV1 enhanced LIF expression in CAFs, thereby activating JAK2/STAT3 signaling in tumor cells. Pharmacological inhibition of STAT3 abolished the tumor-promoting effects of CAFs both in vitro and in vivo.
conclusionsCAF-derived CAV1 promotes bladder cancer progression by activating the LIF-STAT3 signaling axis. Targeting stromal CAV1-mediated STAT3 signaling may represent a promising therapeutic strategy for bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.